Falcão Manuel Sousa, Freitas-Costa Paulo, Beato João Nuno, Pinheiro-Costa João, Rocha-Sousa Amândio, Carneiro Ângela, Brandão Elisete Maria, Falcão-Reis Fernando
Ophthalmology Department. Centro Hospitalar São João. Porto. Portugal.; Department of Sense Organs. Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
Ophthalmology Department. Centro Hospitalar São João. Porto. Portugal; Department of Anatomy. Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
Acta Med Port. 2017 Feb 27;30(2):127-133. doi: 10.20344/amp.7850.
To evaluate the safety and impact on visual acuity, retinal and choroidal morphology of simultaneous cataract surgery and intravitreal anti-vascular endothelial growth factor on patients with visually significant cataracts and previously treated exudative age-related macular degeneration.
Prospective study, which included 21 eyes of 20 patients with exudative age-related macular degeneration submitted to simultaneous phacoemulsification and intravitreal ranibizumab or bevacizumab. The patients were followed for 12 months after surgery using a pro re nata strategy. Visual acuity, foveal and choroidal thickness changes were evaluated 1, 6 and 12 months post-operatively.
There was a statistically significant increase in mean visual acuity at one (13.4 letters, p < 0.05), six (11.5 letters, p < 0.05) and twelve months (11.3 letters, p < 0.05) without significant changes in retinal or choroidal morphology. At 12 months, 86% of eyes were able to maintain visual acuity improvement. There were no significant differences between the two anti-vascular endothelial growth factor drugs and no complications developed during follow-up.
Simultaneous phacoemulsification and intravitreal anti- vascular endothelial growth factor is safe and allows improvement in visual acuity in patients with visually significant cataracts and exudative age-related macular degeneration. Visual acuity gains were maintained with a pro re nata strategy showing that in this subset of patients, phacoemulsification may be beneficial.
Cataract surgery and simultaneous anti-vascular endothelial growth factor therapy improves visual acuity in patients with exudative age-related macular degeneration.
评估同时进行白内障手术和玻璃体内注射抗血管内皮生长因子对患有视力显著下降的白内障且先前已接受治疗的渗出性年龄相关性黄斑变性患者的安全性以及对视力、视网膜和脉络膜形态的影响。
前瞻性研究，纳入20例患有渗出性年龄相关性黄斑变性的患者的21只眼，这些患者同时接受了超声乳化白内障吸除术和玻璃体内注射雷珠单抗或贝伐单抗。术后采用按需治疗策略对患者进行12个月的随访。在术后1、6和12个月评估视力、黄斑和脉络膜厚度变化。
术后1个月（平均视力提高13.4个字母，p < 0.05）、6个月（11.5个字母，p < 0.05）和12个月（11.3个字母，p < 0.05）时，平均视力有统计学意义的显著提高，而视网膜或脉络膜形态无显著变化。在12个月时，86%的患眼能够维持视力改善。两种抗血管内皮生长因子药物之间无显著差异，且随访期间未出现并发症。
同时进行超声乳化白内障吸除术和玻璃体内注射抗血管内皮生长因子是安全的，并且能使患有视力显著下降的白内障和渗出性年龄相关性黄斑变性的患者视力得到改善。按需治疗策略可维持视力提高，表明在这部分患者中，超声乳化白内障吸除术可能有益。
白内障手术联合抗血管内皮生长因子治疗可改善渗出性年龄相关性黄斑变性患者的视力。
